middle.news
How Will Zelira’s $650K R&D Loan Accelerate Its Clinical Breakthroughs?
12:31pm on Thursday 24th of July, 2025 AEST
•
Healthcare
Read Story
How Will Zelira’s $650K R&D Loan Accelerate Its Clinical Breakthroughs?
12:31pm on Thursday 24th of July, 2025 AEST
Key Points
Non-dilutive $650,000 loan facility secured against FY25 R&D tax incentive
Funds to advance HOPE SPV clinical trial and support general working capital
Loan carries a 17% annual interest rate, repayable by November 2025 or upon R&D rebate receipt
Zelira maintains 55% equity in HOPE SPV, which is progressing FDA clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE